Wednesday 3 July 2024

The Pharma Letter Podcast — Episode 5 — Innovation in preleukemia

Pharmaceutical
Simon Wentworth
1 October 2021
episode5-thepharmaletterpodcast

More on this story...

Biotechnology
Syros acquisition and stock sale line up shot at aggressive leukemia
7 December 2020
Biotechnology
The Pharma Letter Podcast — Episode 4 — The state of biotech investing
1 September 2021
Pharmaceutical
The Pharma Letter Podcast — Episode 3 — Psychedelics in medicine
18 August 2021
Biotechnology
FDA puts partial hold on Foghorn's Phase I study of FHD-286
20 May 2022


Related company news

AbbVie acquires Celsius Therapeutics
FDA slaps CRL on AbbVie’s Parkinson’s candidate
Takeda gains European Commission approval for Fruzaqla
āshibio - armed with $40 million - targets success with ex-Gilead antibody
More ones to watch >


Today's issue

Pharmaceutical
Access to medicines key to British voters, survey shows
3 July 2024
Generics
US authorities clear Mylan in long-running antitrust probe
3 July 2024
Biotechnology
Touchlight and LeninBio announce link up
3 July 2024
Pharmaceutical
Pentixapharm pads pipeline with strategic acquisition
3 July 2024
Biotechnology
Beacon Therapeutics raises $170 million in a Series B financing
3 July 2024
Biotechnology
Lilly's Alzheimer’s drug Kisunla wins FDA approval
3 July 2024
Biotechnology
First COPD nod could add billions to Dupixent revenue
3 July 2024

Company Spotlight

A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.




More Features in Pharmaceutical

Access to medicines key to British voters, survey shows
3 July 2024
Pentixapharm pads pipeline with strategic acquisition
3 July 2024
Striking results in Phase III Parkinson’s trial
3 July 2024
ThirtyFiveBio receives grant to continue work on GPR35 blockers
2 July 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze